Type 2 diabetes mellitus (T2DM)
GPCRStructure TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Aleniglipron (GSBR-1290) in Type 2 diabetes mellitus (T2DM). The expected timing is based on the latest available company guidance and may change.
8/6/25- Initiate Ph2 study in T2DM in Q4 2025. 11/6/25: Enrollment ongoing. 05/07/26:- PR No update. 08/06/26:- T2DM with obesity trial data are expected in Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.